Eric Lefkofsky Will Ensure Cancer Treatment Improve Over The Next Decade With Tempus

Eric Lefkofsky has amassed a huge fortune today and is worth billions from his entrepreneurial pursuits and successful companies. Today, Eric is dedicated to successful pushing out Tempus and its technology. In his latest fundraising round, Eric managed to raise more than 70 million dollars for the company, totaling more than 130 million since funding started. Several other companies have backed Tempus as well, but co-founders Eric Lefkofsky and Brad Keywell remain the companies biggest investors.

The original idea for Tempus came to Eric as he saw the effects of cancer up close and personal in his own life. This experience showed him that there needed to be improvements in the healthcare industry, especially when it came to cancer treatments. Luckily for Eric, he has a technological background and he knew there was a way he could help improve this process for people around the world.

Eric has had many successful pursuits in business today, starting from when he first graduated from college. After successfully earning degrees from Michigan Law and the University of Michigan, Eric decided to put his ideas for business into practice and start up his own company. This was just the beginning for Eric, as his first success gave him the success and expereince he needed to create more successful startups. Today he is even an author with a book titled Accelerated Disruption, which goes over the effects of technology in business. Alongside this, Eric regularly speaks and shares his advice to students in the industry of business and technology.

Alongside his successful business practices, Eric Lefkofsky has also started up the Lefkofsky foundation, which he runs with his wife. Together, they help other organizations out there that focus on charity and are non-profit, many of which are located throughout the Chicago area. According to Eric, one cannot be fulfilled without giving back to the community and helping others, especially with such a high level of success. Eric’s latest efforts in business prove this since he is working hard to aid the healthcare industry with Tempus and will invest millions of his own money to ensure its success.

To know more visit @: www.lightbank.com/team/eric-lefkofsky

Famous Urologist Dr. David Samadi Generally Advises Surgery First for Prostate Cancer

Recently Mitt Romney announced he was operated on for prostate by Dr. Thomas Ahrling at the University of California Irvine Hospital because he had a slow-growing tumor. In an article for The Huffington Post, expert urology Dr. David Samadi used the occasion to educate readers on their treatment options if they ever receive a diagnosis of prostate cancer. 27,000 men die of it every year. 16% of American men get prostate cancer in their lifetimes.

Statistically, the odds are high for all older men. The American Cancer Society estimates 164,690 American men will get the dread news in 2018. It’s very rare in men under 40, but the risk goes up as men age. 60% of cases are in men aged 65 or older. And they have two basic treatment options: surgery and radiation therapy.

However, studies show the options are not equal, especially if the cancer remains localized within the prostate. Every cancer is more difficult to successfully treat after it’s begun to spread to other parts of the body. According to the studies, men who have their prostates removed have a near-100% survival rate. Twice as many men who receive the radiation therapy first will die as the men who opt for an operation surgery first. And they are 150% likely to die earlier than the men get treated with surgery first.

On Dr. David Samadi’s website, he has a video of him discussing these statistics as a guest on the Fox News Housecall show. One of the Fox hosts says that many men may be afraid of things related to the surgery. They may fear that the surgery will cause the cancer to spread. Dr. Samadi agrees that fear comes up. He also says many men are afraid that after the surgery they will be incontinent or impotent. But the answer depends on the skill of the surgeon. He said that with experienced surgeons, 95-97% of patients remain continent. Somewhere between 50% and 80% of men retain sexual function. The field of prostate surgery has come a long way in recent years. In his article, he advises men to always discuss this with their surgeon. Ask them how experienced they are. And ask for the percentages of their patients who experience post-surgery urinary incontinence, sexual dysfunction and a return of the prostate cancer. In the video, he also advises patients to ask their doctors whether or not they do open surgery or use robotics.

Dr. David Samadi’s Social Media: twitter.com/drdavidsamadi

Eric Lefkofsky’s Tempus will Bridge the Gap between Genomic and Therapeutic Data

Cancer is one of the most deadly monsters afflicting human health in this modern times. Cancer cases have significantly increased over the past few years. The survival rate has also increased, and it is expected that the trend will continue in the coming years. The increase is attributed to advances in cancer screening and detection methods and steady improvements in treatment processes. As medical researchers grapple with the crisis, most of them have been focusing on diagnosis and refining treatment procedures. In the cancer screening process, cancer institutions focus on patients without prior detected cancer. This effectively removes prior cancer victims from the early detection mechanism of other types of cancers.

Recent research shows that quite a significant number of people diagnosed with cancer are prior cancer victims. Using data from the Surveillance, Epidemiology, and End Results (SEER) program, researchers sought to determine the prior cancer prevalence rates amongst the population diagnosed with cancer. They concentrated on cases reported between January 2009 and December 2013. The research population was also divided into two groups, patients below 65 years and those above 65 years of age.

The outcome of the research indicated that up to 25 percent of adults above 65 years of age had had another cancer detected previously. And up to 11% of persons below 65 years of age had been diagnosed with cancer previously. In the overall population, 18.4% of those diagnosed had a prior cancer history.

Collecting patient data is a great idea, and it was the motivating factor for Eric Lefkofsky when he co-founded Tempus. With better infrastructure, Eric Lefkofsky believes that patient data can be better utilized to determine patient-specific treatment procedures. While there is an enormous amount of patient data, there is no known faster method of linking the data with therapeutic data. The traditional techniques take many days of research and results can rarely apply to current patients.

This is the gap that Eric Lefkofsky, through Tempus, hopes to bridge. The technological platform being developed at Tempus will connect researchers, clinicians, and patients in an effort to improve cancer care. Clinicians will be more capable of figuring out the treatments befitting a particular genomic description of specific patients.

Facebook: https://www.facebook.com/eplefkofsky/